

Updated interim results of a phase 1/2 study to investigate the safety, tolerability, PK, PD, and clinical activity of BION-1301 in patients with IgA nephropathy

Jonathan Barratt¹, Laura Kooienga², Billy Hour³, Irfan Agha⁴, Brian Schwartz⁵, Bess Sorensen⁵, Jeannette Lo⁵, Andrew King⁵, Taher Sathaliya⁵, Sai Prasad Iyer⁵, Aaron Endsley⁶, Alan Glicklich⁵

¹University of Leicester, Leicester, UK; ²Colorado Kidney Care, USA; ³Amicis Research Center, USA; ⁴Liberty Research Center, USA; ⁵Chinook Therapeutics, Inc; and ⁶Certara, Inc.

Disclosures for Presenting Author

Current Employer:	University of Leicester
Consultancy:	Chinook, EMD Serono, Omeros, Calliditas, Novartis, Retrophin, Visterra, Alnylam, Dimerix, George Clinical, and Astellas
Research Funding:	Novartis, GlaxoSmithKline, Calliditas, Visterra, Chinook, and Retrophin
Honoraria:	AstraZeneca
icientific Advisor or Membership:	Editorial Board of Kidney International, Clinical Journal of the American Society of Nephrology, and Clinical Science

Role of APRIL and BION-1301 in IgA Nephropathy

BION-1301 is a novel, humanized monoclonal antibody that binds and blocks APRIL

Potentially disease-modifying mechanism to deplete Gd-IgA1 (**Hit 1**) and prevent pathogenic immune complex formation (**Hit 3**)¹

<u>A PRoliferation Inducing Ligand</u> (APRIL) is a TNF-family cytokine involved in B-cell signaling via TACI and BCMA receptor activation²

Higher APRIL levels in IgAN patients is correlated with higher Gd-IgA1 and proteinuria and lower eGFR² **APRIL gene variants** confer increased risk of IgAN³ The ongoing phase 1/2 trial is investigating BION-1301 in patients with IgAN (NCT03945318)


Objectives

- Safety, tolerability, PK, biomarker effects and preliminary effect on proteinuria
- Proof of mechanism
- Proof of concept
- Explore dose/schedule, intravenous (IV) and subcutaneous (SC) administration

Key Eligibility Criteria, Cohort 1

- Biopsy-proven IgAN within past 10 years
- Total protein excretion ≥0.5 g/24h OR UPCR ≥0.5 g/g based on 24-hour urine collection at screening
- eGFR > 45 mL/min per 1.73 m^{2*}
- Stable on an optimized dose of RASi for ≥ 3 months prior to screening (or intolerant to RASi)

* Or 30 to 45 mL/min/1.73m² if kidney biopsy performed within 2 years prior to Day 1 does not provide evidence of glomerular fibrosis



1. Suzuki et al. *JASN*. 2011; 22(10), 1795-1803. 2. Zai et al. *Medicine*. 2016; 95(11), e3099. 3. Magistroni et al. *Kidney Int*. 2015; 88(5), 974-89. BCMA, B-cell maturation antigen; TACI, transmembrane activator and calcium-modulator and cyclophilin ligand.

Patient Disposition, Interim Safety and PK/PD

Demographics (n=10)		Baseline Characteristics	Median (min, max)
Age, years Median (min, max)	39 (27, 59)	Time from biopsy, years	2.0 (0.2, 3.4)
Sex, male n (%)	9 (90)	Blood pressure (mmHg) – Systolic – Diastolic	127 (113, 133) 83 (69, 88)
Race, white n (%)	10 (100)	eGFR (mL/min/1.73 m ²)*	69 (30, 122)
Ethnicity, Hispanic n (%)	2 (20)	24-hour urine protein excretion $(g/day)^{\dagger}$	1.22 (0.74, 6.47)
	2 (20)	24-hour UPCR (g/g) [†]	0.52 (0.41, 4.55)
Country, US n (%)	10 (100)	Renin-angiotensin system inhibitor use	100 %

Safety

- BION-1301 well tolerated in IgAN patients to date^{*}, with no serious AEs and no treatment discontinuations due to AEs
- 3 patients experienced mild (grade 1) treatment-related AEs, including 1 injection site reaction
- 4 patients experienced mild infections (grade 1), considered not related to treatment
- IgG level below the study defined threshold occurred in one patient, necessitating protocol-mandated withholding of study drug. There have been no infections reported in this patient.

PK/PD


- Rapid reductions in free APRIL confirm durable target neutralization sustained through 1 year
- No anti-drug antibodies observed in patients with IgAN to date
- All patients have transitioned to SC administration for a mean SC treatment duration of 22 weeks (range 5 to 28 weeks)

* eGFR by CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration, n=8; †n=8



*Data cut-off May 6, 2022, with exception of biomarker data cut-off March 10, 2022. AEs, adverse events


BION-1301 Durably Reduces IgA and Gd-IgA1



- BION-1301 durably reduces IgA, IgM, and to a lesser extent, IgG in patients with IgAN
- BION-1301 also produces sustained reductions in Gd-IgA1, the pathogenic IgA variant (Hit 1), demonstrating the potential disease-modifying mechanism of BION-1301
- 6/8 patients have IgA measurements following SC transition; mean SC treatment duration of 15 weeks (range 12-20 weeks) at the most recent IgA measurement



BION-1301 Treatment Results in Sustained, Clinically Meaningful Proteinuria Reductions



- BION-1301 treatment results in proteinuria reductions within 3 months, which are sustained and continue to decline through one year in patients across a range of disease severity
- 6/8 patients have proteinuria measurements following SC transition; mean SC treatment duration of 17 weeks (range 5-24 weeks) at the most recent proteinuria measurement
- 4 patients at the week 52 proteinuria measurement had transitioned to SC dosing for 12-24 weeks (mean 20 weeks); 2 patients at week 76 had 5 and 19 weeks of SC dosing, respectively

Median baseline 24-h urine protein excretion: 1.22 g/day (range: 0.74 - 6.47 g/day)

*Results plotted are based on the least squares mean +/- SE of change from baseline on natural log scale from the MMRM back-transformed to a percent reduction from baseline scale



Interim Data Continues to Demonstrate Disease-Modifying Potential of BION-1301 in Patients with IgAN

Interim BION-1301 IgAN patient data:

- All patients have transitioned to SC dosing and BION-1301 remains well-tolerated, with no treatment discontinuations due to AEs
- Clinically meaningful sustained reductions in proteinuria (24-hour UPCR) within 3 months
- Rapid and sustained free APRIL reductions
- Durable reductions in Gd-IgA1, IgA and IgM, with smaller reductions in IgG
- No anti-drug antibodies have been observed

These data provide early proof-of-concept for the disease-modifying potential of BION-1301 to:

- ✓ deplete pathogenic Gd-IgA1 in patients with IgAN
- reduce proteinuria in patients with IgAN who remain at risk for progression with residual proteinuria despite optimized standard-of-care treatment
- Preliminary response is consistent in patients transitioning from IV to SC

Next Steps:

Enrollment of patients with IgAN is ongoing for Cohort 2, utilizing subcutaneous injection of BION-1301

